Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
10 Results for "
NEK1
" in MedChemExpress (MCE) Product Catalog:
Products (10)
10 Results for "NEK1" in MCE Product Catalog:
3
3 Cited Publications
ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC50 of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 [1].
Target:
Research Areas:
BSc5367 is a potent Nek1 inhibitor with an IC50 of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer [1].
Cat. No.: HY-RS09190
Target:
Research Areas:
NEK1 Human Pre-designed siRNA Set A contains three designed siRNAs for NEK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS18625
Target:
Research Areas:
Nek1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nek1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS25111
Target:
Research Areas:
Nek1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nek1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Target:
Research Areas:
LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer [1] .
Cat. No.: HY-173186
TLK1-IN-1 is a TLK1B inhibitor with a human IC50 of 7.2 μM. TLK1-IN-1 causes accumulation of DNA damage and induces apoptotic cell death in cancer cells. TLK1-IN-1 can be used for the research of metastatic castration-resistant prostate cancer [1].
Cat. No.: HY-103646R
CAS No.: 507487-89-0
Target:
Research Areas:
CK7 (Standard) is the analytical standard of CK7 (HY-103646). This product is intended for research and analytical applications. CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367 [1].
Cat. No.: HY-184544
CAS No.: 2374703-22-5
Research Areas:
CDK8 ligand 2 is a steroidal CDK8 and CDK19 inhibitor with IC50 values of 16 nM and 8 nM, respectively. CDK8 ligand 2 shows no activity against NEK1 (IC50 >10,000 nM). As a target protein ligand, CDK8 ligand 2 is used for the synthesis of the CDK8 PROTAC degrader (HY-111518) [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
